These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32662818)

  • 1. Outcomes of Universal COVID-19 Testing Following Detection of Incident Cases in 11 Long-term Care Facilities.
    Bigelow BF; Tang O; Barshick B; Peters M; Sisson SD; Peairs KS; Katz MJ
    JAMA Intern Med; 2021 Jan; 181(1):127-129. PubMed ID: 32662818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Halting a SARS-CoV-2 outbreak in a US Veterans Affairs nursing home.
    Psevdos G; Papamanoli A; Barrett N; Bailey L; Thorne M; Ford F; Lobo Z
    Am J Infect Control; 2021 Jan; 49(1):115-119. PubMed ID: 33157181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymptomatic and Presymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates in a Multistate Sample of Skilled Nursing Facilities.
    White EM; Santostefano CM; Feifer RA; Kosar CM; Blackman C; Gravenstein S; Mor V
    JAMA Intern Med; 2020 Dec; 180(12):1709-1711. PubMed ID: 33074318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questionnaire-based vs universal PCR testing for SARS-CoV-2 in women admitted for delivery.
    Mei-Dan E; Satkunaratnam A; Cahan T; Leung M; Katz K; Aviram A
    Birth; 2021 Mar; 48(1):96-103. PubMed ID: 33263210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 re-infection: Diagnostic challenges and proposed diagnostic criteria.
    Raveendran AV
    Diabetes Metab Syndr; 2021; 15(2):645-648. PubMed ID: 33663969
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery.
    Savirón-Cornudella R; Villalba A; Zapardiel J; Andeyro-Garcia M; Esteban LM; Pérez-López FR
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():400-404. PubMed ID: 33285496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Universal SARS-CoV-2 Screening for Asymptomatic Patients: A Report From Tokyo, Japan.
    Komori A; Mori H; Kojima Y; Tabe Y; Naito T
    J Cardiothorac Vasc Anesth; 2021 Apr; 35(4):1265-1267. PubMed ID: 33645509
    [No Abstract]   [Full Text] [Related]  

  • 8. Universal PCR screening for coronavirus disease 2019 in asymptomatic patients on admission.
    Nakamura I; Itoi T
    Clin Microbiol Infect; 2021 Apr; 27(4):658-659. PubMed ID: 33221431
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of presymptomatic transmission of COVID-19: evidence from Beijing, China.
    Zhang Y; Muscatello D; Tian Y; Chen Y; Li S; Duan W; Ma C; Sun Y; Wu S; Ge L; Yang P; Jia L; Wang Q; MacIntyre CR
    J Epidemiol Community Health; 2021 Jan; 75(1):84-87. PubMed ID: 32855261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 transmission and case fatality in long-term care facilities during the epidemic first wave.
    Leão T; Severo M; Barros H;
    J Am Geriatr Soc; 2021 Dec; 69(12):3399-3401. PubMed ID: 34409592
    [No Abstract]   [Full Text] [Related]  

  • 11. Mass testing for covid-19 in the UK.
    Gill M; Gray M
    BMJ; 2020 Nov; 371():m4436. PubMed ID: 33199289
    [No Abstract]   [Full Text] [Related]  

  • 12. Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities.
    Yang Q; Saldi TK; Gonzales PK; Lasda E; Decker CJ; Tat KL; Fink MR; Hager CR; Davis JC; Ozeroff CD; Muhlrad D; Clark SK; Fattor WT; Meyerson NR; Paige CL; Gilchrist AR; Barbachano-Guerrero A; Worden-Sapper ER; Wu SS; Brisson GR; McQueen MB; Dowell RD; Leinwand L; Parker R; Sawyer SL
    Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 33972412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal screening for novel coronavirus disease 2019 (COVID-19) for asymptomatic parturients: May not be beneficial at this time.
    Henderson CE; Rezai S; Jackman JM
    J Med Virol; 2021 Mar; 93(3):1198-1200. PubMed ID: 32915477
    [No Abstract]   [Full Text] [Related]  

  • 14. Short-term impact of nursing home SARS-CoV-2 vaccinations on new infections, hospitalizations, and deaths.
    Mor V; Gutman R; Yang X; White EM; McConeghy KW; Feifer RA; Blackman CR; Kosar CM; Bardenheier BH; Gravenstein SA
    J Am Geriatr Soc; 2021 Aug; 69(8):2063-2069. PubMed ID: 33861873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 testing in outbreak-free care homes: what are the public health benefits?
    Green R; Tulloch JSP; Tunnah C; Coffey E; Lawrenson K; Fox A; Mason J; Barnett R; Constantine A; Shepherd W; Ashton M; Beadsworth MBJ; Vivancos R; Hall I; Walker N; Ghebrehewet S
    J Hosp Infect; 2021 May; 111():89-95. PubMed ID: 33453349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitfall of Universal Pre-Admission Screening for SARS-CoV-2 in a Low Prevalence Country.
    Jung J; Kim J; Lim JS; Kim EO; Kim MN; Kim SH
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33946201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic carriage rates and case fatality of SARS-CoV-2 infection in residents and staff in Irish nursing homes.
    Kennelly SP; Dyer AH; Noonan C; Martin R; Kennelly SM; Martin A; O'Neill D; Fallon A
    Age Ageing; 2021 Jan; 50(1):49-54. PubMed ID: 32986806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical v. laboratory-based screening for COVID-19 in asymptomatic patients requiring acute cardiac care.
    Joubert LH; Herbst PG; Doubell AF; Pecoraro AJK
    S Afr Med J; 2020 Sep; 110(11):13088. PubMed ID: 33403976
    [No Abstract]   [Full Text] [Related]  

  • 19. Performance and feasibility of universal PCR admission screening for SARS-CoV-2 in a German tertiary care hospital.
    Krüger S; Leskien M; Schuller P; Prifert C; Weißbrich B; Vogel U; Krone M
    J Med Virol; 2021 May; 93(5):2890-2898. PubMed ID: 33386772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation testing to determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: Testing frequency and public health messaging is key.
    Ferguson J; Dunn S; Best A; Mirza J; Percival B; Mayhew M; Megram O; Ashford F; White T; Moles-Garcia E; Crawford L; Plant T; Bosworth A; Kidd M; Richter A; Deeks J; McNally A
    PLoS Biol; 2021 Apr; 19(4):e3001216. PubMed ID: 33914730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.